Comparative Pharmacology
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus THYREL TRH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERETEK UBT KIT W PRANACTIN versus THYREL TRH.
MERETEK UBT KIT (W/ PRANACTIN) vs THYREL TRH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meretek UBT Kit contains [13C]urea; Helicobacter pylori urease hydrolyzes [13C]urea to produce [13C]CO2, which is detected in breath to indicate active H. pylori infection.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
75 mg oral pranactin (citric acid) dissolved in 200 mL water, administered once for urea breath test.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
None Documented
None Documented
Not applicable; 13C is a stable isotope that is rapidly converted to 13CO2; elimination half-life of CO2 from the body is approximately 5-10 minutes under normal respiratory conditions. Clinical context: 13CO2 appearance in breath peaks at 30 minutes post-dose.
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Urea (13C) is rapidly hydrolyzed by H. pylori urease in the stomach to 13CO2, which is absorbed and exhaled via the lungs; >99% of the 13C dose is eliminated as exhaled 13CO2 within 24 hours. Pranactin (citric acid) is metabolized to CO2 and water; <2% renal elimination.
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent